アルツハイマー病の治療開発の加速:臨床試験の過去と未来

Adam L Boxer¹, Reisa Sperling²

¹Memory and Aging Center, Department of Neurology, Weill Institute of Neuroscience, University of California, San Francisco, San Francisco, CA, USA.

Cell

|October 17, 2023

まとめ

最近のアルツハイマー病 (AD) の抗アミロイド治療は 30年間の研究の結果です重要な要因には,強力な線維性アミロイド減少,早期の患者選択,および高度なバイオマーカーが含まれています.

科学分野:

神経科学
臨床試験
薬物開発

背景:

アルツハイマー病 (AD) 研究は,抗アミロイドβ (Aβ) 抗体に対する最近のポジティブなフェーズ3試験で顕著な進展が見られた.
この治療の成功には何十年もの研究が必要でした

研究の目的:

アルツハイマー病の薬の開発における最近の成功に寄与する要因を分析する.
ADの治療法と臨床試験を進めるための将来の課題と戦略を特定する.

主な方法:

アンチアミロイド治療の過去と最近の臨床試験データをレビューする.
特定の治療標的 (線維性アミロイド) と患者の層分化の役割の分析.
バイオマーカー (アミロイドとタウ・PET) の影響と試験設計の検討

主要な成果:

線維性アミロイドを標的とした強力な治療法の開発と初期段階の患者の選択は重要でした.
アミロイドやタウ・ペットのようなバイオマーカーは過去の試験から得た教訓とともに最近の進歩に不可欠でした
レカネマブとドナネマブの成功は,AD治療の新たな時代を象徴しています.

結論:

将来の取り組みはより効果的で効率的な治療法の開発に焦点を当てなければなりません
新しい試験設計,参加者の多様性向上,血液ベースのバイオマーカーが必要です.
アルツハイマー病の研究の持続的な進歩には公私パートナーシップとイノベーションの奨励が不可欠です

さらに関連する動画

10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

26.8K

09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.4K

関連する概念動画

01:22

Alzheimer's Disease: Treatment

200

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

200

01:26

Alzheimer's Disease: Overview

500

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

500

01:11

Clinical Trials: Overview

3.0K

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

3.0K

01:16

Clinical Trials

6.8K

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...

6.8K

01:28

Preclinical Development: Overview

4.5K

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

4.5K

01:24

Parkinson's Disease: Treatment

281

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

281

関連する実験動画